UK official: Vaccine unlikely to have caused death

September 29, 2009 By RAPHAEL G. SATTER , Associated Press Writer

Enlarge

Flowers at the gate of Blue Coat Church of England School in Coventry England Tuesday Sept. 29, 2009, after a pupil from the school died Monday after receiving the HPV1 Cervarix jab. Health authorities launched an investigation Tuesday into the death of a 14-year-old girl who had just received a vaccine for cervical cancer. Natalie Morton died in a hospital Monday, a few hours after being the given the Cervarix vaccine, which protects against two strains of the human papilloma virus that causes cervical cancer. She was vaccinated at her school in Coventry in central England. (AP Photo/Rui Vieira/PA)

(AP) -- A British health official said Tuesday that the sudden death of 14-year-old girl was very unlikely to have been caused by the vaccine she was given hours before she died.

Natalie Morton, who died in a hospital Monday only hours after being the given the Cervarix vaccine, which protects against the virus that causes cervical cancer, had a "serious underlying medical condition which was likely to have caused death," according to Caron Grainger, the director for public health at Coventry City Council, the English city where the girl went to school.

"We are awaiting further test results which will take some time," Grainger said in a statement. "However, indications are that it was most unlikely that the ... vaccination was the cause of death."

The Cervarix vaccine consists of three injections given over a six-month period, and the shot Morton received at her school had been her first. Morton appeared to be healthy before being given the shot, and her dramatic death sent a ripple of concern across the country.

The council, which has declined to give any further details of the death, did not elaborate on Morton's "underlying medical condition."

Officials have temporarily suspended Coventry's vaccination program and quarantined the batch of vaccine given at the school.

Meanwhile, the U.S. Food and Drug Administration has delayed a decision on whether to approve Cervarix. A decision on the vaccine was expected Tuesday. But GlaxoSmithKline UK, which manufactures Cervarix, said the death in Britain did not influence the FDA's decision to extend its review.

The National Health Service in Coventry said it stopped the vaccination program for two days to give staff administering the vaccine training in how to answer questions from anyone concerned about its safety.

"We fully expect to resume the program in the coming days," the health authority said in a statement.

The state-run National Health Service began offering the Cervarix vaccine to teenage girls last year, and more than 1.4 million doses of the vaccine have been given out so far under the program. The virus is often transmitted through sexual intercourse and authorities wanted to give the vaccine to girls as young as 13 so they are protected by the time they become sexually active.

The cervical cancer vaccine is routinely administered to millions of young girls across Europe and North America. No safety concerns about the vaccines have been raised elsewhere.

"As with any medical intervention ... one can, on rare occasions, see tragic consequences," said Professor Malcolm McCrae, virologist at the University of Warwick. "But overall this is an extremely well-tested vaccine which has been produced in response to a critical health issue - cervical cancer - a disease responsible for almost 1,000 deaths annually in the UK."

Dr. Pim Kon, medical director at GlaxoSmithKline UK, said in a statement that the company is working with the Health Department and health regulators to investigate the case and that the exact cause of death was not yet known.

GlaxoSmithKline shares were down 0.68 percent at 1,243 pence ($19.78) on the London Stock Exchange late Tuesday.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.